Abstract | OBJECTIVES: DESIGN: Randomised study with a 2 x 2 factorial design. SETTING: Provincial teaching hospital. PATIENTS: 33 consecutive patients (40 episodes) admitted with severe congestive cardiac failure (New York Heart Association class III or IV) unresponsive to intravenous loop diuretics for 48 hours. MAIN OUTCOME MEASURES: RESULTS: Diuresis was established during 37 of 40 episodes; of the rest two patients died in hospital. On 36 occasions improvement was sufficient to allow discharge from hospital. Median (range) maximal weight loss was -5.05 (-11.3 to 1.6) kg after the addition of bendrofluazide and -5.6 (-12.2 to 4.8) kg after the addition of metolazone (NS). Area under the body weight loss against time curves showed no significant difference between the two thiazide diuretics. Median (range) maximal weight loss after three days of treatment was -5.4 (-12.2 to 4.8) kg and -5.5 (-10.3 to 1) kg after a more prolonged course of median (range) 5.6 (1 to 13) days (NS). Area under the body weight loss time curves showed no significant difference between the two durations of treatment. Bendrofluazide was associated with fewer electrolyte disturbances. CONCLUSIONS:
|
Authors | K S Channer, K A McLean, P Lawson-Matthew, M Richardson |
Journal | British heart journal
(Br Heart J)
Vol. 71
Issue 2
Pg. 146-50
(Feb 1994)
ISSN: 0007-0769 [Print] England |
PMID | 8130022
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Diuretics
- Bendroflumethiazide
- Urea
- Sodium
- Creatinine
- Potassium
- Metolazone
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Bendroflumethiazide
(therapeutic use)
- Body Weight
(drug effects)
- Creatinine
(blood)
- Diuretics
(therapeutic use)
- Drug Therapy, Combination
- Female
- Heart Failure
(blood, drug therapy)
- Humans
- Male
- Metolazone
(therapeutic use)
- Middle Aged
- Potassium
(blood)
- Sodium
(blood)
- Urea
(blood)
|